Clinical Trial Update: Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE) [Phase 3]

View source ↗

Summary

Phase 3 INFUSE trial evaluating terlipressin for hepatorenal syndrome with acute kidney injury in liver transplant candidates has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatorenal Syndrome
• Kidney Injury

Drugs mentioned

• Terlipressin (terlipressin)

Snippet

Sponsor: University of Pennsylvania | Conditions: Hepatorenal Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2024-10-09